A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome.
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2012
At a glance
- Drugs LX 1031 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- 22 Feb 2012 Results were published in the August 2011 issue of Gastroenterology, according to a Lexicon Pharmaceuticals media release.
- 06 May 2010 Results presented at Digestive Disease Week.
- 06 May 2010 Positive results of this trial have been presented at Digestive Disease Week 2010, according to a Lexicon Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History